]. The gene coding for the human homolog of TRal is located on chromosome 17, and the gene coding for the two /3-isoforms is located on chromosome 3 (2,3). Whereas TRal and its nonfunctional variant, TRa2, are the products of alternate splicing of a single transcript (4, 5) , regulation by alternate promoters in the 5'-upstream region of the TRP gene may be responsible for generation of the messenger RNAs (mRNAs) for TRPl and TRP2 (6) . Although each of these receptor isoforms exhibits a distinctive tissue distribution (6-10) and appears at a specific developmental stage (ll-14) , there is as yet no firm evidence to indicate whether each carries out a specialized function.
In this connection, the role of TRP2 has attracted particular attention. The original description of this isoform by Hodin and Lazar et al. (6) suggested that TRP2 mRNA distribution was limited to the anterior pituitary. The apparently restricted localization of TRP2 mRNA to the pituitary raised the possibility that TR/32 might serve a special role in regulating the production of pituitary TSH. Support for this hypothesis was presented in the report from Childs et al. (15) , who found that most of the TRP2 mRNA in the pituitary is situated in thyrotropes and somatotropes. Each of these cell types secretes a protein known to be regulated by T,. The demonstration that the T, administration produced a significant fall in the level of TR/32 mRNA further strengthened the possibility that TRP2 might play a specialized regulatory role in pituitary hormone secretion.
Although TRP2 initially was believed to be restricted to the anterior pituitary, more recent studies demonstrated low levels of the TRP2 mRNA in specific centers of the developing (11) and adult (16) rat brain. Moreover, studies in our laboratory using antisera directed against specific TR isoforms showed that lo-20% of the total nuclear T, binding capacity in rat liver, heart, kidney, and brain was due to TR/32 (7). These observations were particularly puzzling because we had confirmed the finding by Hodin and Lazar et al. (6) that Northern blot analysis could readily detect a TRP2 signal in pituitary, but not in liver, brain, heart, or kidney. Analysis of RNA by reverse transcription-PCR followed by Southern blot analysis, however, did show the presence of small quantities of TRP2 mRNA in extrapituitary tissues (7). Further, a report by Yen et al. (17) indicated that TR/32 was immunohistochemically present in all anterior pituitary cells, despite an apparent restriction of the mRNA to somatotropes and thyrotropes.
These findings prompted us to undertake the following studies. We first compared the level of pituitary TR isoform protein and mRNA levels in hypo-, eu-, and hyperthyroid rats, believing that the response of the receptor protein would be physiologically more meaningful than the re-sponse of the mRNA. 
Results
Total pituitary nuclear binding capacity in the euthyroid rat averaged 1.87 2 0.24 pmol/mg DNA (Table l) , with an association constant of 2.75 2 0.23 X lo9 M-I. The effectiveness of therapy was documented by the stabilization in weight of hypothyroid animals and the progressive weight loss in hyperthyroid animals. Neither hypo-nor hyperthyroidism caused a significant change in binding capacity or affinity, consistent with earlier reports from this laboratory (27) of relatively high nuclear T, binding capacity compared to that in other tissues and extending previous studies in liver showing that neither the binding affinity nor the binding capacity is influenced by the thyroidal state (28). In agreement with the earlier report of Hodin et al. (9), alteration of the thyroid state had no significant effect on the total binding capacity.
Of additional interest is the finding that the thyroidal state appears to have no significant effect on the binding capacity, affinity, or distribution of the constituent isoforms. Figure 1 illustrates the isoform composition of total pituitary nuclear binding capacity in euthyroid animals. In the euthyroid rat pituitary, TRal, TRPl, and TRP2, respectively, represent 25.6%, 16.3%, and 58.1% of the total nuclear T, binding capacity. There was no significant difference in pituitary receptor isoform distribution among eu-, hypo-, and hyperthyroid states. As in previous studies (7), an antiserum directed against an epitope common to all three T,-binding receptor isoforms cleared over 95% of all binding in these extracts, thus excluding any major contribution from unidentified receptor species. Further, the similarity in the slopes of the individual isoform components in Fig. 1 supports previously published data from other tissues (7), which indicate that the T, association constants of the TR isoforms are similar. We next determined the pituitary content of the mRNAs coding for the TR isoforms (Fig. 2) . The pituitary TR/32 mRNA reference standard was linear in the range examined (Fig. 3) . In confirmation of the findings of Hodin et al. (9), thyroid hormone significantly reduced the level of TR/32 mRNA in the transition from hypothyroid to euthyroid states (P < 0.05; Table 11 ). However, we found no change in the level of this mRNA in the transition from the euthyroid to the hyperthyroid state, a transition not examined previously. Our data fail to suggest major effects of thyroid hormone status on the levels of TRPl and TRcrl mRNAs, contrary to Hodin et al. (9), who found a 350% increase in TRPl mRNA and a 20% fall in TRal mRNA in the transition from the hypothyroid to the hyperthyroid state.
We also compared the TR isoform protein/mRNA ratios in the euthyroid pituitary to those in extrapituitary tissues, including brain, liver, heart, and kidney. Our curiosity in this area was aroused by the finding of substantial quantities of TR/32 protein in extrapituitary tissue despite our failure to identify TR/32 mRNA by conventional Northern analysis (7). We measured the level of isoform receptor protein per mg DNA from results listed in Table 1 and from previous studies from our laboratory (7). Although the level of TRP2 mRNA in extrapituitary tissues was too low to be measured directly, Fig. 2 . The computer-generated best-fit line fails to intersect the origin, suggesting that the autoradiography film is nonlinear at low exposures. r2 = 0 999 . .
we obtained an upper limit for such values by determining the smallest amount of pituitary RNA that would result in a measurable signal on Northern analysis (Fig. 4) . As detailed in Materi& and Methods, the available data allowed us to express the receptor mRNA and receptor protein in terms of molecules per cell. Table 2 summarizes the results of this analysis.
As previously discussed (7), there is surprisingly wide variation in the calculated isoform TR protein/ mRNA molar ratio. For TRal, the highest ratio among the tissues examined is in pituitary (18,000) and the lowest in brain (144); for TRPl, the highest ratio is also in the pituitary (1680), and the lowest, in the brain (40). In the case of TRP2, however, the ratio in extrapituitary tissues far exceeds those of all other isoforms: in the liver, this value is in excess of 120,000. Whereas the level of TRP2 protein molecules per cell in all instances is above 178 (kidney), the number of mRNA molecules of TRP2 in extrapituitary tissues varies from less than 0.0045 (heart) to less than 0.0069 (liver)/cell.
Discussion
In the present studies, we have attempted to achieve two goals: 1) to assess the effect of altered thyroidal status on Regarding the first of these objectives, we set out to determine whether thyroid hormone-induced changes in TRfi2 nuclear binding capacity would parallel those in its n-RNA. For changes in TRp2 mRNA levels to be physiologically significant, the changes in receptor protein and activity levels should mirror those in the mRNA. Our studies are consistent with the previous report by Hodin et al. (9) showing that the administration of Ta to hypothyroid animals resulted in a significant fall in TRp2 mRNA. As we did not observe an effect of excess T3 in euthyroid rats, we conclude that the effect of Ta is restricted to the transition between hypothyroid and euthyroid states. Of special interest to us was the observation that despite the fall in TRP2 mRNA, the TRp2 binding capacity did not change significantly in response to T, administration in either euthyroid or hypothyroid animals.
These findings reflect other examples of discordant alterations in TR protein and mRNA, observations that point to posttranscriptional effects. Thus, Rodd et al. have shown (13) that the concentration of TRPl rises several-fold in rat liver during the first weeks of life, with no discernible change in the mRNA level. Lane et al. (29) showed that starvation reduces the hepatic T, binding capacity without a change in mRNA concentrations.
Our studies do not rule out the possibility that TRP2 could play an important role in the regulation of pituitary TSH regulation. As we did not independently measure TR/32 levels in thyrotropes and somatotropes, we cannot exclude the possibility that changes in thyroid status could have induced oppositely directed changes in thyrotropes and somatotropes, thus leading to unchanged levels of total TRP2 protein in the anterior pituitary. Because pooling of rat pituitaries was technically necessary, differences in individual animal responses may have been obscured. Further, a specific role for TR/32 in regulating TSH and GH need not be dependent directly on alterations in TR/32 protein.
Our second question relates to the potential implications of the wide range in receptor protein/mRNA ratios defined by data from the current and previous studies (7) Table 2 . The receptor protein/mRNA ratio varied from 40 (TRpl, brain) to more than 120,000 (TRj32, liver) over a 3,000-fold range. The concentration of receptors per cell ranged from 178 (TR/32, kidney) to 5,240 (TRp2, pituitary), a 29-fold range. Thus, the major factor contributing to the wide range of protein/mRNA ratios is the calculated concentration of mRNA molecules per cell, from less than 0.00453 (TRp2, heart) to 20.2 (TRpl, kidney), a more than 4460-fold range.
Examination of the data in Table 2 raises an interesting problem. On the average, each cell in all tissues studied contains at least 178 /32 receptor protein molecules. In a relatively homogeneous tissue such as liver, the inference that each cell contains nuclear receptors is supported by immunocytochemical studies showing that nuclei from essentially all visible hepatocytes exhibit a TRP2 signal (7). In contrast, analogous estimates of TRP2 receptor mRNA in extrapituitary tissues showed that the concentration was significantly less than 1 molecule/cell. Calculated values for TRP2 mRNA per cell in extrapituitary tissues suggest that, on the average, less than 1 in 200 cells contains receptor mRNA.
These considerations raise questions regarding potential mechanisms that could account for the presence of TR/32 receptor in every cell, but for the presence of mRNA in only 1 of every 200 cells. One explanation is that there is a systematic overestimation of TR/32 receptors in extrapituitary tissues due of nonspecific interactions of the IgG preparations used in quantitating TRp2. This appears highly unlikely. Evidence reported in an earlier study (7) indicated that the three distinctive anti-TRP2 antisera that were tested reacted only with TR/32 translation products. Two of these antisera were prepared against different regions of the specific amino-terminal domain of TRP2. The three antisera immunoprecipitated identical fractions of the total T3 binding capacity from hepatic extracts. Other data were presented that argued against the possibility that the anti-TR/32 serum nonspecifically interacts with other receptor isoforms or unrelated molecules.
Another potential explanation is that the TRP2 protein synthesized in one cell is transported to adjacent cells. Although such a phenomenon is theoretically possible, there is, to our knowledge, no precedent for paracrine transport of nuclear receptor proteins. Further, the distribution of TRP2 in the liver and other tissues, as visualized by immunostaining of histological sections, does not reveal the spatial gradients that one might anticipate under such circumstances.
The most likely explanation, we believe, is that the halftime of disappearance (tl,.J for the TRP2 mRNA is extremely rapid compared with that of the protein in extrapituitary tissues. A short mean residence time for the mRNA implies that the receptor gene is expressed only periodically in any one cell. In contrast, a prolonged t,,, for the TRP2 protein, in relationship to the t,,, of its mR.NA, could explain the presence of one or more receptor protein molecules per cell at all times. Such a mechanism could account for both the exceedingly low density of mRNAs and the substantial representation of the TR/32 receptor in nearly all nuclei of liver hepatocytes. Higher concentrations of TR/32 mRNA in the pituitary may be the result of a slower fractional rate of mRNA turnover in the pituitary than in peripheral tissue. Such a mechanism also could explain the discrepancy between the limited mRNA (15), but widespread protein (17), TRP2 distribution in the pituitary. Run-on assays and in sittl hybridization studies to assess the rate of turnover of TRP2 mRNA in peripheral tissues are in progress. 
